Gilead: AIDS Activists
Are Not For Sale

Gilead is the poster child for drug company price gouging.

Gilead has doubled the price they charge to safety net providers for the prevention drug Descovy in just two years.

Gilead tries to cover its tracks by giving millions of dollars to the same AIDS organizations it has decimated.

Gilead should know by now that AIDS activists are not for sale.

Gilead must immediately restore the money they have taken from AIDS organizations.

Gilead: AIDS Activists
Are Not For Sale

Gilead is the poster child for drug company price gouging.

Gilead has doubled the price they charge to safety net providers for the prevention drug Descovy in just two years.

Gilead tries to cover its tracks by giving millions of dollars to the same AIDS organizations it has decimated.

Gilead should know by now that AIDS activists are not for sale.

Gilead must immediately restore the money they have taken from AIDS organizations.

AHF Protests Against Gilead

AHF TAKES A STAND

AIDS Healthcare Foundation led a rally and protest at drug maker Gilead Sciences’ headquarters in Foster City, CA; Washington, DC; and Miami, FL. The protest targeted Gilead’s move to undermine safety net providers’ access to 340B drug pricing program benefits. Gilead now becomes the 15th drug company to illegally restrict access to certain drugs.

Washington, DC

Foster City, CA

Miami, FL

In less than two years, Gilead has more than doubled the cost of its HIV medication, Descovy, for the lifesaving 340B program from $445.11 in Q2, 2020 to $987.55 in Q2, 2022

#GreedyGilead goes Global!

Gilead has priced several of its HIV and hepatitis C drugs out of reach for many people, refused to register some medications in developing countries, and consistently uses its patent monopolies to block attempts to introduce cheaper, generic versions of its medicines.

AHF is taking its grassroots campaign global to raise awareness about Gilead’s shameful practices and calling on the company to do the following:

Stop evergreening patents on existing HIV/AIDS drugs like Truvada – this is exploitation, not innovation.
Open the license for the generic production of the hepatitis C drug Harvoni to all low- and middle-income countries, without exception.
For the duration of the COVID-19 pandemic, sell or license remdesivir for generic distribution at a nonprofit price.

License technology to produce cryptococcal meningitis to generic manufacturers.
Link executive compensation to the impact on positive public health outcomes and access to medicines in developing countries.